Drug maker Celgene Corp.'s (CELG) board authorized the repurchase of up to an additional $3.0 billion of its common stock. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by management and in accordance with applicable requirements of the Securities and Exchange Commission.
Year-to-date, Celgene has bought back nearly $1.8 billion of its common stock and has exhausted the earlier $2.5 billion stock buyback authorization. Celgene has repurchased around $6.5 billion of its common stock over the last 4 years.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.